Evotec and Related Sciences Expand Integrated Drug Discovery and Development
Friday, February 10, 2023
Evotec announced that the Company has extended and expanded its integrated multi-target drug discovery agreement with Related Sciences, to continue to grow joint portfolio of drug development candidates through 2030, leveraging Evotec’s industry-leading capabilities across the full R&D continuum.
• Evotec and related sciences are collaborating to combine complementary capabilities to advance a portfolio of new transformative medicines.
• The partnership oversees a growing portfolio of more than 15 multi-modality drug discovery programmes
• Extension and expansion through 2030 to include evotec’s industry-leading capabilities in the discovery of covalent inhibitors
The Evotec-RS partnership aims to bring together a unique set of complementary capabilities to efficiently select, discover, and develop new, precisely targeted medicines for unmet patient needs.
To support the growing portfolio of more than 15 discovery-stage assets, the partners are expanding the collaboration to include Evotec’s leading-edge capabilities in covalent inhibitor discovery, leveraging and building upon Evotec’s custom covalent libraries and novel screening approaches to discover exciting new class of highly potent and selective covalent medicines for eligible targets.
